Prazosin

What it is

Prazosin is a quinazoline-derived alpha-1 adrenergic receptor blocker, taken by mouth as 1 mg, 2 mg and 5 mg capsules. It was the first of its chemical class of blood-pressure drugs. It is licensed in the United States only for high blood pressure, but is widely prescribed off-label for trauma-related nightmares.

What the research says

Prazosin relaxes small arteries by blocking alpha-1 receptors, lowering blood pressure by a modest amount: a Cochrane review of alpha blockers put the best estimate at -8/-5 mmHg and said even that is likely an overestimate. Its most contested use is off-label, for nightmares and insomnia in post-traumatic stress disorder. A 2025 meta-analysis of 10 randomised trials found it improved nightmares and insomnia but not overall PTSD symptoms, while the largest single trial, the 304-participant VA PACT trial published in the New England Journal of Medicine, found no benefit at all. Its best-documented harm is first-dose syncope, about 1% at starting doses of 2 mg or more.

Evidence grade: Disputed.

How it works

Drug class: Alpha-1 adrenergic receptor antagonist (quinazoline alpha-blocker)

Prazosin blocks alpha-1 adrenergic receptors on the muscle of small arteries, so the signal that normally keeps them tightened is interrupted and they widen. Total peripheral resistance falls and blood pressure drops in both lying and standing positions, with the diastolic pressure most affected. Unlike older alpha blockers it usually does not cause a reflex speeding of the heart. The label states plainly that the exact mechanism of its blood-pressure action is unknown. (Source 1)

What it is used for

• The licensed use. A 2012 Cochrane review of 10 trials in 1,175 people put the trough blood-pressure lowering of alpha blockers at about -8/-5 mmHg and called even that estimate likely an overestimate. The label's claim of reduced cardiovascular events rests on antihypertensive drugs as a class, not on outcome trials of prazosin itself. Evidence: limited. (Source 2)
• A 2025 meta-analysis of 10 randomised trials in 648 patients found prazosin significantly improved insomnia and nightmares but not overall PTSD symptoms. The largest single trial, with 304 veterans, found no difference from placebo on any of its three primary outcomes. The two results have not been reconciled. Evidence: disputed. (Source 3)
• One 12-week double-blind trial in 92 people without PTSD found a greater fall over time in drinks per week and heavy drinking days on prazosin than on placebo, with more drowsiness and oedema. The authors describe it as promising and call for independent replication rather than a settled result. Evidence: limited. (Source 4)

Interactions

• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) (label): Taking a PDE-5 inhibitor with prazosin adds their blood-pressure-lowering effects together and can cause symptomatic low blood pressure. (Source 5)
• Diuretics and other blood-pressure-lowering drugs (label): Adding a water tablet or another blood-pressure drug produces an additive fall in blood pressure, which is why the label describes reducing the prazosin dose and re-titrating. (Source 5)
• Beta-blockers such as propranolol (label): The label records that low blood pressure may develop in people given prazosin who are also taking a beta-blocker such as propranolol. (Source 6)
• Alcohol (clinical trial): No disulfiram-type or pharmacokinetic alcohol interaction is documented in the label. What the literature records instead is prazosin being given deliberately to people who drink: in a 12-week randomised trial in alcohol use disorder, prazosin was associated with a greater fall in drinking over time, with more drowsiness and oedema than placebo. Alcohol itself lowers blood pressure acutely, so the additive-hypotension caution the label applies to other blood-pressure-lowering agents is the relevant framing. (Source 4)
• Digoxin, insulin and oral diabetes drugs, benzodiazepines, allopurinol, colchicine, aspirin and indomethacin (label): The label lists these as given alongside prazosin without an adverse interaction being seen, though it describes this as limited clinical experience rather than formal interaction studies. (Source 5)

Stopping it

• There is no documented physical dependence or withdrawal syndrome with prazosin, and the trials do not report rebound hypertension. What is reported for the off-label PTSD use is symptom return: a 2023 case series notes prazosin is often continued indefinitely because of reports of symptoms coming back when it is stopped, and that there is no standard guidance for a discontinuation trial. (Source 7)
• That case series is three patients, which is the weakest design in the hierarchy; it describes continued remission after stopping in those three, which is the opposite of what the indefinite-continuation practice assumes. (Source 7)
• Starting again after a break matters as much as stopping: the label warns that syncope can occur with the first dose, and directs that patients always be started on the 1 mg capsule, because the 2 mg and 5 mg capsules are not indicated for initial therapy. (Source 8)

What goes wrong

Prazosin can cause fainting with sudden loss of consciousness, usually within 30 to 90 minutes of the first dose. (Source 6)

• Official position, Certainty not rated.
• Size: Not stated as a denominator; drawn from the investigational clinical trial programme.
• Who: Patients started on prazosin, particularly at an initial dose of 2 mg or greater.
• How long: First dose and during rapid dose increases.
• Result: The label states the incidence of syncopal episodes is approximately 1% in patients given an initial dose of 2 mg or greater, and that episodes have occasionally been preceded by tachycardia of 120-160 beats per minute.
• Funding: FDA-approved labelling.

The incidence of syncopal episodes is approximately 1% in patients given an initial dose of 2 mg or greater.

Dizziness, headache and drowsiness are common on prazosin, each reported in roughly 1 in 13 to 1 in 10 patients in the trial programme. (Source 9)

• Official position, Certainty not rated.
• Size: More than 900 patients in clinical trials, plus later marketing experience.
• Who: Patients treated with prazosin hydrochloride.
• How long: Not stated.
• Result: Dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpitations 5.3%, nausea 4.9%. No placebo comparison is given for these figures, so they are not placebo-adjusted rates.
• Funding: FDA-approved labelling.

dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpitations 5.3%, and nausea 4.9%.

Prolonged erections and priapism have been reported with prazosin after marketing, and the label directs that an erection lasting longer than 4 hours needs immediate medical help because untreated priapism can cause permanent damage. (Source 10)

• Case report, Very low certainty.
• Size: Not stated; post-marketing reports.
• Who: People taking alpha-1 blockers including prazosin.
• How long: Not stated.
• Result: No rate is given. The label states that if priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.
• Funding: FDA-approved labelling.

Prolonged erections and priapism have been reported with alpha-1 blockers including prazosin in post marketing experience. In the event of an erection that persists longer than 4 hours, seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result.

Intraoperative floppy iris syndrome during cataract surgery has been reported in people on alpha-1 blockers including prazosin. (Source 11)

• Case report, Very low certainty.
• Size: Not stated; post-marketing reports.
• Who: People on alpha-1 blocker therapy undergoing cataract surgery.
• How long: Not stated.
• Result: No rate is given in the label. It is described as a variant of small pupil syndrome occurring during cataract surgery.
• Funding: FDA-approved labelling.

During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha-1 blocker therapy

What the evidence supports

A meta-analysis of randomised trials found prazosin improved nightmares and insomnia in PTSD, but not overall PTSD symptoms. (Source 3)

• Meta-analysis, Low certainty.
• Size: 10 randomised controlled trials, 648 patients.
• Who: Patients with post-traumatic stress disorder, military and civilian.
• How long: Trial durations varied and were examined as a moderator.
• Result: Insomnia standardised mean difference -0.654, p = 0.043; nightmares SMD -0.641, p = 0.025; overall PTSD symptoms SMD -0.428, p = 0.077 (not significant). Higher benzodiazepine use was associated with greater improvement, which the authors call unexpected.
• Funding: not stated in the abstract.

Analysis revealed prazosin significantly improved insomnia (SMD = -0.654, p = 0.043) and nightmares (SMD = -0.641, p = 0.025), but not overall PTSD symptoms (SMD = -0.428, p = 0.077).

In the PACT trial, new or worsening suicidal ideation was recorded less often on prazosin than on placebo. (Source 12)

• Randomized trial, Low certainty.
• Size: 304 participants, 152 per arm.
• Who: Veterans with chronic PTSD and frequent nightmares.
• How long: 10 weeks for the primary outcomes, 26 weeks total.
• Result: New or worsening suicidal ideation occurred in 8% of participants assigned to prazosin versus 15% assigned to placebo. This was an adverse-event tally in a trial that found no efficacy, not a prespecified efficacy outcome.
• Funding: Department of Veterans Affairs Cooperative Studies Program.

The adverse event of new or worsening suicidal ideation occurred in 8% of the participants assigned to prazosin versus 15% of those assigned to placebo.

What the evidence does not support

The largest randomised trial of prazosin for PTSD nightmares found no benefit over placebo on any primary outcome. (Source 12)

• Randomized trial, Moderate certainty.
• Size: 304 participants randomised, 152 to prazosin and 152 to placebo.
• Who: Veterans at 13 Department of Veterans Affairs medical centres with chronic PTSD and frequent nightmares.
• How long: 26 weeks, with primary outcomes at 10 weeks.
• Result: Between-group difference in CAPS item B2 (distressing dreams) 0.2 (95% CI -0.3 to 0.8; P=0.38); Pittsburgh Sleep Quality Index 0.1 (95% CI -0.9 to 1.1; P=0.80); Clinical Global Impression of Change 0 (95% CI -0.3 to 0.3; P=0.96). No significant differences at 26 weeks or on secondary outcomes.
• Funding: Department of Veterans Affairs Cooperative Studies Program.

At 10 weeks, there were no significant differences between the prazosin group and the placebo group in the mean change from baseline in the CAPS item B2 score (between-group difference, 0.2; 95% confidence interval [CI], -0.3 to 0.8; P=0.38), in the mean change in PSQI score (between-group difference, 0.1; 95% CI, -0.9 to 1.1; P=0.80), or in the CGIC score (between-group difference, 0; 95% CI, -0.3 to 0.3; P=0.96).

The same Cochrane review could not estimate how often alpha blockers cause harm, because the trials were short and often did not report adverse effects. (Source 13)

• Systematic review, Very low certainty.
• Size: 10 trials, 1,175 participants.
• Who: Adults with primary hypertension.
• How long: 3 to 12 weeks, which the review identifies as too short.
• Result: No usable incidence of harms could be derived; withdrawals due to adverse effects were sought but the reporting was inadequate.
• Funding: not stated in the abstract.

The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short duration of the trials

Where the evidence is mixed

Alpha blockers lower blood pressure only modestly, and a Cochrane review judged even that estimate inflated. (Source 13)

• Systematic review, Low certainty.
• Size: 10 trials, 1,175 participants with a baseline blood pressure of 155/101 mm Hg.
• Who: Adults with primary hypertension given fixed-dose alpha blocker monotherapy.
• How long: 3 to 12 weeks.
• Result: Best estimate of trough blood-pressure lowering -8/-5 mmHg, described by the review as unsatisfactory and likely an overestimate; no clinically meaningful differences between individual alpha blockers.
• Funding: not stated in the abstract.

The best but unsatisfactory estimate of the trough BP lowering efficacy for alpha blockers is -8/-5 mmHg.

In a trial for alcohol use disorder, prazosin reduced drinking over time but caused more drowsiness and swelling than placebo. (Source 4)

• Randomized trial, Low certainty.
• Size: 92 randomised, 80 completed the titration period and were analysed.
• Who: Adults with alcohol use disorder but without PTSD.
• How long: 12 weeks, double-blind, target 4 mg morning, 4 mg afternoon, 8 mg at bedtime.
• Result: A significant condition-by-week interaction for number of drinks and for heavy drinking days, favouring prazosin; participants on prazosin were more likely to report drowsiness and oedema. The authors call the result promising and ask for independent replication.
• Funding: not stated in the abstract.

Participants in the prazosin condition were more likely to report drowsiness and edema than participants in the placebo condition.

Where the research disagrees

Whether prazosin helps nightmares in post-traumatic stress disorder

• Raskind and colleagues, the VA Cooperative Studies PACT trial, New England Journal of Medicine 2018, Randomised, double-blind, placebo-controlled trial in 304 veterans at 13 VA centres: In this trial involving military veterans who had chronic PTSD, prazosin did not alleviate distressing dreams or improve sleep quality. (Source 12)
• A 2025 systematic review and meta-regression in Progress in Neuro-Psychopharmacology and Biological Psychiatry, Meta-analysis of 10 randomised trials in 648 patients, which includes the PACT trial among them: These findings suggest that prazosin effectively reduces insomnia and nightmares in PTSD patients. (Source 3)

How much

• Reference intake: Dosing is set by the prescriber. The FDA label records, as a position in its 2026-07-10 version, an initial dose of 1 mg two or three times a day, with maintenance doses most commonly in the range of 6 mg to 15 mg daily in divided doses. It states that patients should always be started on the 1 mg capsule. (Source 14)
• Upper limit: The label's stated ceiling is a total daily dose of 20 mg in divided doses, above which it says efficacy usually does not increase, with a few patients possibly benefiting up to 40 mg daily. This is a label position, not a safety threshold established by trials. (Source 14)
• Studied: The PACT trial escalated prazosin over five weeks to a daily maximum of 20 mg in men and 12 mg in women. (Source 15)
• Studied: The alcohol use disorder trial titrated to 4 mg in the morning, 4 mg in the afternoon and 8 mg at bedtime by the end of week 2. (Source 4)

A common belief, and what the research shows

The belief: Prazosin is a proven treatment for PTSD nightmares.

What the research shows: It is a contested one. The pooled analysis of ten trials does find an effect on nightmares and insomnia, reporting that prazosin "significantly improved insomnia (SMD = -0.654, p = 0.043) and nightmares (SMD = -0.641, p = 0.025), but not overall PTSD symptoms". The single largest trial, in 304 veterans, found the opposite: "prazosin did not alleviate distressing dreams or improve sleep quality". Both results stand in the literature. The use is also off-label - prazosin's only US approval is for high blood pressure.

Questions and answers

What is it?

Prazosin is a prescription tablet, supplied as 1 mg, 2 mg and 5 mg capsules, that blocks alpha-1 adrenergic receptors. It was the first drug of its chemical class, a quinazoline derivative, developed as a blood-pressure medicine. In the United States its only approved use is high blood pressure. (Source 16)

What does it do in the body?

Prazosin widens small arteries by blocking the alpha-1 receptors that normally keep them tightened, so the resistance the heart pumps against falls and blood pressure drops both lying and standing, with the lower (diastolic) number most affected. Unlike older alpha blockers it does not usually trigger a reflex fast heartbeat. The label is candid that the exact mechanism of its blood-pressure action is unknown. (Source 1)

Is it good or bad for you?

Context decides. For blood pressure the effect is real but modest - a Cochrane review of ten trials put alpha blockers at about -8/-5 mmHg and called that likely an overestimate. For PTSD nightmares the evidence splits: a meta-analysis of ten trials found benefit, the single largest trial found none. The best-documented harm is fainting with the first dose, about 1% at a starting dose of 2 mg or more, along with common dizziness, headache and drowsiness. (Source 13)

How do you get more of it?

Prazosin is a prescription medicine, not a nutrient, so there is no food or supplement source and no reason to want more of it. The amount a person takes is set by a prescriber; the label records an initial 1 mg two or three times a day as a position, rising slowly, with most people maintained between 6 mg and 15 mg daily in divided doses. (Source 14)

If it is harmful, what reduces it?

Prazosin leaves the body quickly: the label records a plasma half-life of two to three hours, so levels fall within hours of a missed or stopped dose. In overdose or excessive low blood pressure the label describes supportive treatment and lying the patient down rather than any antidote or removal procedure. (Source 1)

Why might someone be low in it or missing it?

This does not apply in the nutrient sense - nobody is naturally deficient in prazosin. People do end up off it: the label notes that only about 90% of an oral dose is absorbed relative to a solution, giving peak levels about 65% of those from solution, and in practice the common reasons for having none in the system are a missed dose, a stopped prescription, or stopping because of dizziness or fainting. (Source 1)

Which whole foods contain it or feed it?

No whole food contains prazosin. No food or supplement interaction is documented in the label we read; the interactions it records are with other medicines - PDE-5 inhibitors, diuretics and other blood-pressure drugs, and beta-blockers such as propranolol. The label lists a number of drugs given alongside prazosin without an adverse interaction appearing. (Source 5)

What happens if you do not have it?

Nothing happens from not having prazosin unless it was treating something. If it was being taken for blood pressure, stopping removes a modest reduction of roughly 8/5 mmHg. If it was being taken off-label for trauma nightmares, a 2023 case series records that it is often continued indefinitely precisely because symptoms are reported to return when it stops - although in those three patients they did not. (Source 7)

How can you test for it?

There is no routine blood test for prazosin levels in ordinary care, and none is described in the label. What is monitored is the effect, not the drug: blood pressure measured lying and standing, since the label records that blood pressure is lowered in both positions and that fainting typically happens 30 to 90 minutes after the first dose. For the off-label PTSD use the trials measured symptoms with rating scales such as the Clinician-Administered PTSD Scale and the Pittsburgh Sleep Quality Index, not drug levels. (Source 6)

References

1. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, CLINICAL PHARMACOLOGY section (SPL effective 2026-07-10). 2026. Read the source
2. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, INDICATIONS & USAGE section (SPL effective 2026-07-10). 2026. Read the source
3. Progress in neuro-psychopharmacology & biological psychiatry. Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis.. 2025. PMID 39828080, DOI 10.1016/j.pnpbp.2025.111253. Read the source
4. The American journal of psychiatry. Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.. 2018. PMID 30153753, DOI 10.1176/appi.ajp.2018.17080913. Read the source
5. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, DRUG INTERACTIONS section (SPL effective 2026-07-10). 2026. Read the source
6. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, WARNINGS section, first-dose syncope paragraph (SPL effective 2026-07-10). 2026. Read the source
7. Frontiers in psychiatry. Case series: Continued remission of PTSD symptoms after discontinuation of prazosin.. 2023. PMID 37151970, DOI 10.3389/fpsyt.2023.1172754. Read the source
8. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, WARNINGS section, management of syncope and starting strength (SPL effective 2026-07-10). 2026. Read the source
9. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, ADVERSE REACTIONS section, most frequent and 1% to 4% reactions (SPL effective 2026-07-10). 2026. Read the source
10. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, WARNINGS section, Priapism subsection (SPL effective 2026-07-10). 2026. Read the source
11. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, ADVERSE REACTIONS section, rarely reported and post-marketing events (SPL effective 2026-07-10). 2026. Read the source
12. The New England journal of medicine. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. (RESULTS and CONCLUSIONS sections). 2018. PMID 29414272, DOI 10.1056/NEJMoa1507598. Read the source
13. The Cochrane database of systematic reviews. Blood pressure lowering efficacy of alpha blockers for primary hypertension.. 2012. PMID 22895943, DOI 10.1002/14651858.CD004643.pub3. Read the source
14. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, DOSAGE & ADMINISTRATION section (SPL effective 2026-07-10). 2026. Read the source
15. The New England journal of medicine. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. (METHODS section). 2018. PMID 29414272, DOI 10.1056/NEJMoa1507598. Read the source
16. DailyMed (US National Library of Medicine), SPL from ANI Pharmaceuticals, Inc.. Prazosin Hydrochloride Capsules, USP 1 mg, 2 mg and 5 mg - FDA label, DESCRIPTION section (SPL effective 2026-07-10). 2026. Read the source